journal
MENU ▼
Read by QxMD icon Read
search

Bladder Cancer

journal
https://www.readbyqxmd.com/read/27500204/beyond-cisplatin-i
#1
Edward M Messing
No abstract text is available yet for this article.
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500203/clinical-trials-corner
#2
(no author information available yet)
No abstract text is available yet for this article.
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500202/elevated-derived-neutrophil-to-lymphocyte-ratio-corresponds-with-poor-outcome-in%C3%A2-patients-undergoing-pre-operative-chemotherapy-in%C3%A2-muscle-invasive-bladder-cancer
#3
Kim E M van Kessel, Lorraine M de Haan, Elisabeth E Fransen van de Putte, Bas W G van Rhijn, Ronald de Wit, Michiel S van der Heijden, Ellen C Zwarthoff, Joost L Boormans
Background: Platinum-based pre-operative chemotherapy (POC) for muscle-invasive bladder cancer (MIBC) increases the complete pathological response rate at cystectomy and improves overall survival. However, 60% of MIBC patients still has muscle-invasive disease at cystectomy despite POC. Therefore, accurate prediction of response to POC is an important clinical need. We hypothesized that an elevated neutrophil-to-lymphocyte ratio (NLR) corresponds with adverse outcome in patients undergoing POC and radical cystectomy...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500201/obesity-and-outcomes-in-patients-with-metastatic-urothelial-carcinoma
#4
Amanda Leiter, John Doucette, Susan Krege, Chia-Chia Lin, Noah Hahn, Thorsten Ecke, Guru Sonpavde, Aristotle Bamias, William K Oh, Matthew D Galsky
Background: Obesity has been associated with worse outcomes in patients with clinically localized urothelial cancer. However, this impact has not been evaluated in metastatic disease. Objective: To assess the impact of obesity on outcomes of patients with metastatic urothelial cancer. Methods: Data from 537 patients were aggregated from eight phase II and phase III clinical trials investigating first-line cisplatin-based combination therapy in metastatic urothelial cancer. Chemotherapy regimen, adverse events, treatment response, and survival outcomes were compared across body mass index (BMI) and body surface area (BSA) categories...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500200/assessing-symptom-burden-in-bladder-cancer-an-overview-of-bladder-cancer-specific-health-related-quality-of-life-instruments
#5
Bernard J Danna, Michael J Metcalfe, Erika L Wood, Jay B Shah
Background: A key component to monitoring and investigating patient QOL is through patient reported health related quality of life (HRQOL) outcome measures. Many instruments have been used to assess HRQOL in bladder cancer and each instrument varies in its development, validation, the context of its usage in the literature and its applicability to certain disease states. Objective: In this review, we sought to summarize how clinicians and researchers should most appropriately utilize the available HRQOL instruments for bladder cancer...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500199/the-relationship-between-centralization-of-care-and-geographic-barriers-to-cystectomy-for-bladder-cancer
#6
Martin F Casey, Juan Wisnivesky, Valerie H Le, Umut Sarpel, Kristian D Stensland, William K Oh, Matthew D Galsky
Background: Centralization of cystectomy treatment for bladder cancer, while associated with improved outcomes, may impose geographic barriers to care. However, whether this effect may be counterbalanced by an increased number of high volume centers has not previously been explored. Objective: To characterize changes in geographic disparities to high volume cystectomy centers over time. Methods: Data on all inpatient admissions for cystectomy in New York State (NYS) from 1997-2011 was obtained from the Department of Health...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500198/a-systematic-review-of-the-diagnostic-and-prognostic-value-of-urinary-protein-biomarkers-in-urothelial-bladder-cancer
#7
Jamie J D'Costa, James C Goldsmith, Jayne S Wilson, Richard T Bryan, Douglas G Ward
For over 80 years, cystoscopy has remained the gold-standard for detecting tumours of the urinary bladder. Since bladder tumours have a tendency to recur and progress, many patients are subjected to repeated cystoscopies during long-term surveillance, with the procedure being both unpleasant for the patient and expensive for healthcare providers. The identification and validation of bladder tumour specific molecular markers in urine could enable tumour detection and reduce reliance on cystoscopy, and numerous classes of biomarkers have been studied...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500197/systematic-review-and-meta-analysis-on-the-impact-of-hexaminolevulinate-versus-white-light-guided-transurethral-bladder-tumor-resection-on-progression-in-non-muscle-invasive-bladder-cancer
#8
Georgios Gakis, Omar Fahmy
Introduction: Although there is evidence that hexaminolevulinate (HAL)-based transurethral bladder tumor resection (TURBT) improves the detection of Ta-T1 non-muscle-invasive bladder cancer (NMIBC) as well as carcinoma in situ there is uncertainty about its beneficial effects on progression. Material and Methods: A systematic literature search was conducted according to the PRISMA statement to identify studies reporting on HAL- vs. white-light (WL-) based TUR-BT in non-muscle invasive bladder cancer between 2000 and 2016...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500196/the-future-of-intravesical-drug-delivery-for%C3%A2-non-muscle-invasive-bladder-cancer
#9
Laura Douglass, Mark Schoenberg
Despite being the fifth most common cancer in the United States, minimal progress has been made in the treatment of bladder cancer in over a decade. Intravesical instillation of Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC) has been in use for over 30 years and remains the standard treatment in cases of intermediate and high risk disease. Despite the relative success of intravesical BCG, unmet needs in the treatment of NMIBC persist. These challenges include disease recurrence and progression even with treatment with BCG, as well as issues regarding its availability and patient tolerability...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376148/paper-alert
#10
Edward M Messing
No abstract text is available yet for this article.
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376147/clinical-trials-corner
#11
(no author information available yet)
No abstract text is available yet for this article.
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376146/the-impact-of-blue-light-cystoscopy-with-hexaminolevulinate-hal-on-progression-of-bladder-cancer-a-new-analysis
#12
Ashish M Kamat, Michael Cookson, J Alfred Witjes, Arnulf Stenzl, H Barton Grossman
Background: The International Bladder Cancer Group (IBCG) recently proposed a new definition of disease progression in non-muscle invasive bladder cancer (NMIBC), including change in T-stage, change to T2 or higher or change from low to high grade. Objective: To establish whether blue light cystoscopy with hexaminolevulinate (HAL) impacts the rate of progression and time to progression using the revised definition. Methods: An earlier long-term follow-up of a controlled Phase III study reported outcomes following blue light cystoscopy with HAL (255 patients) or white light (WL) cystoscopy (261 patients) in NMIBC patients...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376145/benefit-of-adjuvant-chemotherapy-and-pelvic-lymph-node-dissection-in-pt3-and-node-positive-bladder-cancer-patients-treated-with-radical-cystectomy
#13
Peter J Boström, Tuomas Mirtti, Bas van Rhijn, Neil E Fleshner, Antonio Finelli, Matti Laato, Michael A Jewett, Malcom J Moore, Srikala Sridhar, Martti Nurmi, Ian F Tannock, Alexandre R Zlotta
Background: Benefits of adjuvant chemotherapy (AC) and extent of pelvic lymph node dissection (PLND) in radical cystectomy (RC) are debated. Results from randomized trials are still expected. Objective: To analyze the effects of AC and PLND in two academic centers with opposite policies regarding their use. Methods: 581 bladder cancer patients who underwent RC without neoadjuvant chemotherapy, from Toronto (University Health Network), Canada, and Turku University Hospital, Finland were included. Disease specific survival (DSS) and failure patterns were assessed...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376144/a-multi-center-international-study-assessing-the-impact-of-differences-in-baseline-characteristics-and-perioperative-care-following-radical-cystectomy
#14
Takahiro Osawa, Cheryl T Lee, Takashige Abe, Norikata Takada, Khaled S Hafez, Jeffrey S Montgomery, Alon Z Weizer, Brent K Hollenbeck, Ted A Skolarus, Sachiyo Murai, Nobuo Shinohara, Todd M Morgan
Background: To identify potential avenues for quality improvement, we compared the variations in clinical practice and their association with perioperative morbidity and mortality following radical cystectomy (RC) for bladder cancer in the United States (US) and Japan. Methods: We reviewed our retrospectively collected database of 2240 patients who underwent RC for bladder cancer at the University of Michigan (n = 1427) and in 21 Japanese institutions (n = 813) between 1997 and 2014. We performed a systematic comparison of clinical and perioperative factors and assessed predictors of perioperative morbidity and mortality...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376143/a-nonselective-cyclooxygenase-inhibitor-enhances-the-activity-of-vinblastine-in-a-naturally-occurring-canine-model-of-invasive-urothelial-carcinoma
#15
Deborah W Knapp, Audrey Ruple-Czerniak, José A Ramos-Vara, James F Naughton, Christopher M Fulkerson, Sonia I Honkisz
Background: Chemotherapy is expected to remain an important part of invasive urothelial carcinoma (UC) treatment. Strategies to enhance chemotherapy efficacy are needed. Objective: To determine the chemotherapy-enhancing effects of a nonselective cyclooxygenase (COX) inhibitor on vinblastine in a naturally-occurring canine model of invasive UC. Methods: With IACUC approval, privately-owned dogs with naturally-occurring histologically-diagnosed invasive UC, expected survival ≥6 weeks, and informed owner consent were randomly allocated to receive vinblastine (2...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376142/using-analytic-morphomics-to-understand-short-term-convalescence-after-radical-cystectomy
#16
Amy N Luckenbaugh, Brent K Hollenbeck, Jeffrey S Montgomery, Cheryl T Lee, Scott M Gilbert, Rodney L Dunn, Jeffrey F Friedman, Michael J Englesbe, Stewart C Wang, John M Hollingsworth
Background: Data from the general surgery literature suggests that patient morphometric data obtained from preoperative imaging may help predict a patient's risk around surgery. Objectives: In this context, we evaluated for associations between psoas muscle area and short-term convalescence following radical cystectomy. Methods: After identifying patients who underwent radical cystectomy at our institution (2008 to 2013), we calculated their psoas muscle area from staging computed tomography scans using established analytic morphomic techniques...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376141/do-african-american-patients-treated-with-radical-cystectomy-for-bladder-cancer-have-worse-overall-survival-accounting-for-pathologic-staging-and-patient-demographics-beyond-race-makes-a-difference
#17
Deborah R Kaye, Joseph K Canner, Max Kates, Mark P Schoenberg, Trinity J Bivalacqua
Background: It is estimated that 74,000 men and women in the United States will be diagnosed with bladder cancer and 16,000 will die from the disease in 2015. The incidence of bladder cancer in Caucasian males is double that of African American males, but African American men and women have worse survival. Although factors contributing to this disparity have been analyzed, there is still great uncertainty as to why this disparity exists. Objective: To evaluate whether the disparities in bladder cancer survival after radical cystectomy for transitional cell carcinoma (TCC) of the bladder amongst African American (AA) and Caucasian patients is attributable to patient demographics, year of diagnosis, and/or tumor characteristics...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376140/bacillus-calmette-gu%C3%A3-rin-bcg-treatment-failures-with-non-muscle-invasive-bladder-cancer-a-data-driven-definition-for-bcg-unresponsive-disease
#18
Ryan L Steinberg, Lewis J Thomas, Sarah L Mott, Michael A O'Donnell
Objective: To create the first data-driven definition for those unlikely to benefit from further BCG treatment. Materials and Methods: The database created for the Phase 2 BCG-Interferon-α 2B (IFN) study was queried and BCG failure patients were identified (n = 334). Full study protocols have previously been published. Separate models were constructed for analysis of patients with any CIS (pure or concomitant) and pure papillary disease. Variables considered included age, gender, stage, grade, tumor size and focality (for papillary only), number of prior BCG courses, and prior BCG failure interval...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376139/collaborating-to-move-research-forward-proceedings-of-the-10th-annual-bladder-cancer-think-tank
#19
Ashish M Kamat, Piyush Agarwal, Trinity Bivalacqua, Stephanie Chisolm, Sia Daneshmand, James H Doroshow, Jason A Efstathiou, Matthew Galsky, Gopa Iyer, Wassim Kassouf, Jay Shah, John Taylor, Stephen B Williams, Diane Zipursky Quale, Jonathan E Rosenberg
The 10th Annual Bladder Cancer Think Tank was hosted by the Bladder Cancer Advocacy Network and brought together a multidisciplinary group of clinicians, researchers, representatives and Industry to advance bladder cancer research efforts. Think Tank expert panels, group discussions, and networking opportunities helped generate ideas and strengthen collaborations between researchers and physicians across disciplines and between institutions. Interactive panel discussions addressed a variety of timely issues: 1) data sharing, privacy and social media; 2) improving patient navigation through therapy; 3) promising developments in immunotherapy; 4) and moving bladder cancer research from bench to bedside...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376138/summary-and-recommendations-from-the-national-cancer-institute-s-clinical-trials-planning-meeting-on-novel-therapeutics-for-non-muscle-invasive-bladder-cancer
#20
Seth P Lerner, Dean F Bajorin, Colin P Dinney, Jason A Efstathiou, Susan Groshen, Noah M Hahn, Donna Hansel, David Kwiatkowski, Michael O'Donnell, Jonathan Rosenberg, Robert Svatek, Jeffrey S Abrams, Hikmat Al-Ahmadie, Andrea B Apolo, Joaquim Bellmunt, Margaret Callahan, Eugene K Cha, Charles Drake, Jonathan Jarow, Ashish Kamat, William Kim, Margaret Knowles, Bhupinder Mann, Luigi Marchionni, David McConkey, Lisa McShane, Nilsa Ramirez, Andrew Sharabi, Arlene H Sharpe, David Solit, Catherine M Tangen, Abdul Tawab Amiri, Eliezer Van Allen, Pamela J West, J A Witjes, Diane Zipursky Quale
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and multi-disciplinary group of clinical and research stakeholders and included leaders from NCI, FDA, National Clinical Trials Network (NCTN), advocacy and the pharmaceutical and biotech industry. The meeting goals and objectives were to: 1) create a collaborative environment in which the greater bladder research community can pursue future optimally designed novel clinical trials focused on the theme of molecular targeted and immune-based therapies in NMIBC; 2) frame the clinical and translational questions that are of highest priority; and 3) develop two clinical trial designs focusing on immunotherapy and molecular targeted therapy...
2016: Bladder Cancer
journal
journal
52783
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"